These drugs specifically target factors and receptors such as vascular endothelial growth factors (VEGFs) and their receptors (VEGFRs), epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), the BRAFV600E mutation, and immunotherapy with immune checkpoint inhibitors (ICIs), the latter being the latest revolution in tumor treatment [1]. This evidence concerns the gene ERBB2 and neoplasm.